- Home
- FTHY vs RGNX Comparison
FTHY vs RGNX Comparison
Compare FTHY & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTHY
- RGNX
- Stock Information
- Founded
- FTHY 2020
- RGNX 2008
- Country
- FTHY United States
- RGNX United States
- Employees
- FTHY N/A
- RGNX N/A
- Industry
- FTHY Investment Managers
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FTHY Finance
- RGNX Health Care
- Exchange
- FTHY Nasdaq
- RGNX Nasdaq
- Market Cap
- FTHY 535.0M
- RGNX 459.1M
- IPO Year
- FTHY N/A
- RGNX 2015
- Fundamental
- Price
- FTHY $14.65
- RGNX $7.62
- Analyst Decision
- FTHY
- RGNX Strong Buy
- Analyst Count
- FTHY 0
- RGNX 12
- Target Price
- FTHY N/A
- RGNX $36.00
- AVG Volume (30 Days)
- FTHY 176.7K
- RGNX 1.7M
- Earning Date
- FTHY 01-01-0001
- RGNX 11-06-2024
- Dividend Yield
- FTHY 10.93%
- RGNX N/A
- EPS Growth
- FTHY N/A
- RGNX N/A
- EPS
- FTHY N/A
- RGNX N/A
- Revenue
- FTHY N/A
- RGNX $84,327,000.00
- Revenue This Year
- FTHY N/A
- RGNX $2.34
- Revenue Next Year
- FTHY N/A
- RGNX $243.67
- P/E Ratio
- FTHY N/A
- RGNX N/A
- Revenue Growth
- FTHY N/A
- RGNX N/A
- 52 Week Low
- FTHY $12.66
- RGNX $7.21
- 52 Week High
- FTHY $14.74
- RGNX $28.80
- Technical
- Relative Strength Index (RSI)
- FTHY 48.78
- RGNX 36.08
- Support Level
- FTHY $14.34
- RGNX $8.06
- Resistance Level
- FTHY $14.76
- RGNX $10.52
- Average True Range (ATR)
- FTHY 0.15
- RGNX 0.76
- MACD
- FTHY -0.02
- RGNX -0.19
- Stochastic Oscillator
- FTHY 53.45
- RGNX 12.39
About FTHY First Trust High Yield Opportunities 2027 Term Fund
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.